Rosetta Genomics (NASDAQ: ROSG) today announced it will hold a conference call and webcast on December 18, 2009 at 8:30 a.m. Eastern time, in which management will provide a business update, discuss progress on its development pipeline and answer questions. Third quarter financial results will also be covered. A press release also will be issued prior to the conference call.
To access the live conference call, U.S. and Canadian participants may dial (866) 239-5859; international participants may dial (702) 495-1913. To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291. The access code for the replay is 46130893. The replay will be available until December 21, 2009.
A live audio webcast of the call will also be available on the "Investors" section of the company's website, www.rosettagenomics.com. An archived webcast will be available on the Company's website approximately two hours after the event, and will be archived for 30 days thereafter.
About Rosetta Genomics
Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company's first three microRNA-based tests, miRview™ squamous, miRview™ mets, and miRview™ meso, are commercially available through its Philadelphia-based CLIA-certified lab. Rosetta Genomics is the 2008 winner of Wall Street Journal's Technology Innovation Awards in the medical/biotech category. To learn more, please visit www.rosettagenomics.com.
Forward-Looking Statements
Various statements in this release concerning Rosetta's future expectations, plans and prospects, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed under "Key Information - Risk Factors" in Rosetta's Annual Report on Form 20-F for the year ended December 31, 2008 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
Contacts:
Company Contact:
Rosetta Genomics
Ron Kamienchick, 646-509-1893
investors@rosettagenomics.com
or
Investor
Contacts:
Lippert/Heilshorn & Associates
Kim Sutton
Golodetz, 212-738-3777
kgolodetz@lhai.com
or
Bruce
Voss, 310-691-7100
bvoss@lhai.com
